Recombinant anti-CD20 humanized monoclonal antibody (Shanghai Pharma)

重组抗CD20人源化单抗（上海医药集团）

Report date: 2024/05/09 20:00:08

Base Information

Drug NameRecombinant anti-CD20 humanized monoclonal antibody (Shanghai Pharma)
Drug Alias NameRecombinant Humanized Anti-CD20 Monoclonal AntibodyB001B-001B001AB001-A +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionCD20-directed cytolytic effectsAnti-CD20Antibody-dependent cell-mediated cytotoxicity (ADCC) effects
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsNeuromyelitis OpticaMultiple SclerosisLymphoma, Non-Hodgkin +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesShanghai Pharmaceuticals Holding Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesYongzhuo Boji (Shanghai) Biomedical Technology Co LtdShanghai Pharmaceuticals Holding Co LtdShanghai Crosslink Pharmaceutical R & D Co Ltd
Inactive CompaniesN/A
Active IndicationsNeuromyelitis OpticaMultiple SclerosisLymphoma
Inactive IndicationsLymphoma, Non-Hodgkin

Other Information

ATC CodeN/A
Related LinksN/A